Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PAN004
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Wacker Chemie AG
Deal Size : Undisclosed
Deal Type : Collaboration
Wacker and Pantherna Enhance Collaboration in mRNA Biopharmaceutical Development
Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.
Brand Name : PAN004
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 07, 2024
Lead Product(s) : PAN004
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Wacker Chemie AG
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : mRNA-based Vaccine
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Evaxion Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Evaxion and Pantherna Announce Promising Preclinical mRNA Vaccine Data
Details : The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 08, 2023
Lead Product(s) : mRNA-based Vaccine
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Evaxion Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : mRNA-based Regenerative Medicine
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approa...
Brand Name : PTXmRNAs
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 04, 2022
Lead Product(s) : mRNA-based Regenerative Medicine
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?